Bacci G, Picci P, Orlandi M, Avella M, Manfrini M, Pignatti G, Dallari D, Manduchi R
Bone Tumor Center, Bologna, Italia.
Tumori. 1987 Aug 31;73(4):331-6. doi: 10.1177/030089168707300402.
In 163 patients with osteosarcoma of the extremities treated with adjuvant chemotherapy, serum alkaline phosphatase (SAP) levels were evaluated before treatment and successively closely monitored in an attempt to determine whether serum levels of this enzyme had clinical value in predicting the course of the disease. Of 121 patients with elevated preoperative SAP levels, 78 (64%) recurred. Of 42 patients with normal preoperative SAP levels, only 8 (19%) recurred (P less than 0.00001). Of the 140 patients locally treated with amputation, SAP returned to normal values in 77 patients; 46 of these (59%) relapsed. Of the 21 patients whose SAP remained elevated after amputation, all but 2 relapsed (90%). Among 119 patients with normal postoperative values of SAP, at the time of relapse SAP resulted elevated in 22 of 41 patients (53%). These data confirm that in osteosarcoma, preoperative SAP levels have a definite value in establishing the prognosis and that posttreatment follow-up examination should include SAP determination, since persistent elevated or increasing values herald the appearance of a recurrence.
在163例接受辅助化疗的肢体骨肉瘤患者中,在治疗前评估血清碱性磷酸酶(SAP)水平,并对其进行连续密切监测,以确定该酶的血清水平在预测疾病进程方面是否具有临床价值。术前SAP水平升高的121例患者中,78例(64%)复发。术前SAP水平正常的42例患者中,仅8例(19%)复发(P<0.00001)。在140例接受截肢局部治疗的患者中,77例患者的SAP恢复到正常水平;其中46例(59%)复发。在截肢后SAP仍升高的21例患者中,除2例外均复发(90%)。在术后SAP值正常的119例患者中,复发时41例患者中有22例(53%)的SAP升高。这些数据证实,在骨肉瘤中,术前SAP水平对判断预后有一定价值,治疗后的随访检查应包括SAP测定,因为持续升高或上升的值预示着复发的出现。